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There are sex differences in a number of behaviors elicited by amphetamine (AMPH). The purpose of the present experiment 
was to determine if there are also sex differences in the sensitization of the locomotor activity and stereotypy produced by 
repeated intermittent AMPH treatment, and whether this is accompanied by sex differences in dopamine (DA) metabolism. It 
was found that female rats showed greater and more rapid sensitization of locomotor activity and stereotyped behavior than 
males. In addition, prior exposure to AMPH was associated with an elevation in resting striatal dihydroxyphenylacetie acid 
(DOPAC) to DA ratios in female, but not male rats, suggesting a sex difference in one neurochemical correlate of sensitization. 
As a group, males were more variable and heterogeneous in their response to repeated AMPH treatment, because they were 
divisible into two neurochemically distinct subgroups on the basis of their change in behavior and females were not. This 
heterogeneity may make it more difficult to identify neurochemical correlates of sensitization in males. It is suggested that there 
is a sex difference in the responsiveness of brain DA systems to repetitive activation, and this contributes to individual variation 
in the susceptibility to sensitization. 
INTRODUCTION 
The repeated intermittent administration of 
psychomotor stimulant drugs produces a progres- 
sive enhancement in many stimulant-induced be- 
haviors, a phenomenon known as behavioral sen- 
sitization. For example, the locomotion, stereo- 
typy and rotational behavior produced by amphe- 
tamine (AMPH) usually show a more rapid onset, 
an increased intensity, or a longer duration with 
successive in jec t ions  12,24'33"44,61. Although most 
animals are sensitized by repeated AMPH ad- 
ministration, there are also large individual differ- 
ences in the rate and extent of sensiti- 
zation 30'36"42'45"60. Little is known, however, 
about factors which influence the development of 
sensitization. Genetic factors clearly contribute to 
individual variation in the susceptibility to sensiti- 
zation, but how they do so is unknown 15,3°,45,58. 
In addition, the sex of an animal and the presence 
of testicular hormones modulate the sensitization 
of AMPH-induced rotational behavior 44,5°. Fe- 
male rats show greater sensitization of AMPH- 
elicited rotational behavior than males, and cas- 
tration of male rats enhances the sensitization of 
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rotational behavior. These latter studies suggest 
that a testicular hormone directly or indirectly 
retards the development of sensitization. 
It is not known, however, if there are sex differ- 
ences in the sensitization of other AMPH- 
induced behaviors, such as locomotion or stereo- 
typy. AMPH produces many different behavioral 
effects by altering activity in multiple and 
functionally heterogeneous mesotelencephalic 
dopamine (DA) systems (refs. 11,19,23,65 for 
reviews). It is possible, therefore, that the sex of 
an animal influences the sensitization of other 
AMPH-induced behaviors differently than ro- 
tational behavior. To explore this issue the present 
experiment was designed to determine the 
influence of sex on the sensitization of locomotion 
and stereotyped behavior produced by repeated 
AMPH treatment, and on associated changes in 
DA metabolism 48'49. 
MATERIALS AND MET H O D S 
SubJects 
Adult male and female Sprague-Dawley- 
derived Holtzman rats (Holtzman Co., Madison, 
WI) initially weighing 250-350 g were housed 
individually in a light-controlled room (14: 10 h 
light: dark cycle, lights on at 08.00 h) and provid- 
ed with free access to food and water. All treat- 
ment and test procedures were carried out 
between 08.00 and 17.00 h. 
Apparatus for recording motor activity 
Continuous measures of locomotor activity 
were obtained with Digiscan Animal Activity 
Monitors (Omnitech Electronics, Columbus, 
OH), which detect movement by use of 32 
infrared light beam sensors and emitters located 
2.54 cm apart about the perimeter of a Plexiglas 
test chamber (40.6 x 40.6 x 30.5 cm). The moni- 
tors were connected to a microprocessor 
(Digiscan Analyzer, Omnitech Electronics) that 
automatically recorded several different measures 
of motor activity over 5-min intervals. The data 
from the Digiscan system presented here repre- 
sent the distance animals traveled in inches, 
which was estimated by interpolating the distance 
between successive beam interruptions. 
Rating stereotyped behavior 
In addition to the automated analysis of loco- 
motion described above, the animals were rated 
for stereotyped behavior during 1 min obserwi- 
tion periods at 10 and 20 min following the in- 
jection, and every 20 min thereafter for a total of 
2 h (i.e. a total of 7 ratings). The rater was blind 
to the treatment conditions. Two different rating 
scales were used. (a) An overall stereotypy score 
was based on the scale described by Ellinwood 
and Balster ~3. On this scale, 1--asleep (lying 
down, eyes closed), 2 = inactive (lying down, eyes 
open), 3 = normal in place activities (normal 
grooming, occasional walking, turning), 4 = nor- 
mal, alert, active (moving about cage, sniffing or 
rearing intermittently), 5 = hyperactive (running 
movement characterized by rapid changes in po- 
sition), 6 = slow patterned activity (repetitive ex- 
ploration of cage at normal levels of activity), 
7 = fast patterned activity (repetitive exploration 
of cage with hyperactivity), 8 = restricted 
(remaining in the same place with fast repetitive 
head and limb movements), and 9 = dyskinetic- 
reactive (backing-up, jumping, seizures, abnor- 
mally maintained postures, and/or dyskinetic 
movements). (b) Stereotyped sniffing behavior 
was rated separately, according to both its du- 
ration (1 = discontinuous, 2--continuous) and 
intensity (1 = mild, 2 = moderate, 3 = intense), 
as described by Rebec and Sega143. A single 
stereotypy score for sniffing at each rating interval 
was derived by multiplying the duration and 
intensity scores. 
Experimental design and protocol 
Male and female animals received an intra- 
peritoneal (i.p.) injection of o-amphetamine sul- 
fate (AMPH) once every 4 days for a total of 
10 injections, but behavior was monitored only 
following the 1st, 4th, 7th and 10th injections 
('test days'). On these test days each animal was 
removed from its home cage and placed indivi- 
dually in the test chamber. Following a 15-min 
habituation period, each animal received an 
injection of AMPH and was immediately re- 
placed in the test chamber for 2 h. On the days 
when AMPH was administered but behavior was 
not monitored (i.e. injection days 2, 3, 5, 6, 8 
and 9) the animals were not exposed to the test 
chambers, but were immediately returned to their 
home cage following the injection. This was to 
minimize drug-environment conditioning effects 
associated with repeated AMPH adminis- 
tration 39"41'55'62"64 (cf. ref. 59). 
Male rats (n = 11) always received 3.0 mg/kg 
AMPH (weight of the salt) dissolved in 0.9~o 
saline (3.0mg/ml). In contrast, the females 
(n = 17) were subdivided into two groups which 
received two different doses of AMPH (2.6 mg/kg 
or 1.78 mg/kg), for the following reasons. Male 
and female rats metabolize AMPH at different 
rates, and females attain slightly higher brain 
levels of AMPH than males when the same sys- 
temic dose is administered 3'w'22"34. One of the 
doses (2.6 mg/kg) controlled for this sex differ- 
ence in AMPH metabolism by equating brain 
levels of the drug. In a previous study using rats 
of the same age, same strain and same supplier, 
a range (1-10 mg/kg) of systemic doses of AMPH 
was administered to male and females rats, and 
whole brain and striatal concentrations of AMPH 
were measured at various points in time after the 
injection 3. From this study it was determined that 
an i.p. injection of 2.6 mg/kg to females produced 
the same brain concentrations of AMPH as did 
3.0mg/kg in males. Therefore, all females 
received 2.6 mg/kg AMPH on the days when 
AMPH was administered but behavior was not 
monitored (i.e. injection days 2, 3, 5, 6, 8 and 9). 
This dose will be referred to as the 'sensitizing' 
dose. A comparison of males and females re- 
ceiving equivalent sensitizing doses of AMPH (in 
terms of brain concentrations) is used as one 
index of sex differences in the response to 
repeated AMPH treatment. 
A second, and even more conservative control 
group, was also included. Females in this group 
(n = 9) received 1.78 mg/kg of AMPH on test 
days (i.e. days when behavior was monitored). 
This dose will be referred to as the 'challenge' 
dose, because on the last injection day (i.e. the day 
10challenge) all the females received the 
challenge dose of 1.78 mg/kg (i.e. also females 
pretreated with 2.6 mg/kg). Based on the Becker 
et al. 3 study, it is estimated that the challenge dose 
(1.78 mg/kg) produced brain levels of AMPH in 
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females that were 33~o lower than in males 
receiving 3.0 mg/kg AMPH. For the sake of sim- 
plicity, females that received the challenge dose on 
each test day will be referred to as the 'female- 
1.78' group, and females that received 2.6 mg/kg 
on all days but the last challenge test day as the 
'female-2.6' group. 
All animals in each group were also given a 
single i.p. injection of 0.9~o saline (1 ml/kg) 3-4 
days following the last AMPH injection, and the 
same procedures were followed as described 
above (except behavior was recorded for only 1 h 
after the injection). 
Females were tested without regard for their 
estrous cycle, and it is recognized that this could 
increase the variance in this group.because of 
estrous cycle-related fluctuations in dopaminergic 
activity and response to AMPH 3. It was thought, 
however, that this was preferable to taking daily 
vaginal smears to track the estrous cycle, which 
would introduce an additional confounding 
stressful manipulation; especially since it is 
known that prior stress interacts with AMPH 
sen sitiz ation 1,2,45. 
Neurochemical methods and procedures 
Eight to 13 days after the last injection of 
AMPH all animals were killed by decapitation, 
and the brains were rapidly removed ( <  40 s) and 
placed in ice-cold saline. In addition, a group of 
naive control male and female rats that received 
no prior treatment were included. These animals 
were untreated to exclude the changes in DA ac- 
tivity produced by repeated injections of sa- 
line 5~'68. The brains were dissected by a person 
(T.E.R.) blind to treatment conditions. The dis- 
section procedure was very similar to that 
described by Heffner et al.16, except the frontal 
cortex included only the medial frontal cortex 
located anterior to the genu of the corpus callo- 
sum. The tissue samples were weighed and placed 
into tubes which contained 250#1 of 0.05 N 
perchloric acid and 2.0 ng/10/11 of the internal 
standard, dihydroxybenzylamine (DHBA). The 
tissue was homogenized and then centrifuged at 
5000 g for 45 min at 2-4  °C. The supernatant 
was filtered using 0.2 #m regenerated cellulose 
membrane filters and stored in vials at - 20 ° C. 
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The concentrations of dopamine (DA), 3,4- 
dihydroxyphenylacetic acid (DOPAC), 5-hydro- 
xytryptamine (5-HT; serotonin) and 5-hydroxy- 
indoleacetic acid (5-HIAA) were assayed by high- 
performance liquid chromatography with electro- 
chemical detection (HPLC-EC). Briefly, the 
HPLC system employed a Brownlee reverse 
phase C-18 column and an LC-4 electrochemical 
detector with a glassy carbon electrode (Bio- 
Analytical Systems, Lafayette, IN). The mobile 
phase was a citric acid-sodium phosphate buffer 
(pH 3.35) containing 25-30 mg/1 octyl sulfonate 
and 8-10~o methanol. The detector potential was 
set at + 0.74 V versus an Ag/AgC1 reference elec- 
trode. 
Statistical analyses 
The stereotypy rating scores were analyzed 
using non-parametric statistical techniques, in- 
cluding Profile a n a l y s e s  37, Friedman's analyses of 
variance for repeated measures and the Wilcoxon 
signed-ranks test for matched pairs. Either the 
median test or the Mann-Whitney U-test was 
used for individual comparisons. (The median 
test is not as powerful as the Mann-Whitney 
U-test, but is preferable if there are many tied 
scores35.) Locomotor activity scores and the 
neurochemical data were analyzed using parame- 
tric statistics that included one- or two-way ana- 
lyses of variance for repeated measures, or t-tests 
for individual a priori comparisons. All compari- 
sons were based on two-tailed probabilities, un- 
less otherwise noted. 
RESULTS 
Sensitization of stereotyped behavior 
On the challenge test day (day 10) some ani- 
mals received a lower dose of AMPH than they 
received during each of the sensitization sessions 
(i.e. injections 1-7). Therefore, group differences 
were determined for the sensitization sessions 
separately from the challenge test. 
Sensitization sessions (injections 1- 7). Following 
the first injection of AMPH, the overall stereotypy 
scores for female-2.6 animals were greater than 
for males (U = 3, P < 0.001; Fig. 1A), but repeti- 
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Fig. 1. The effects of repeated amphetamine (AMPH) treat- 
ment on overall stereotypy and stereotyped sniffing behavior 
in male and female rats. Male animals (n = 11) received 
3.0 mg/kg AMPH, and female rats either 2.6 or 1.78 mg/kg 
('female-2.6' [n = 8] and 'female-l.78' In = 9] animals, re- 
spectively; see text). All females received a challenge in- 
jection of 1.78 mg/kg AMPH on the tenth day of AMPH 
treatment, whereas males again received 3.0 mg/kg. The 
points represent the average (+ S.E.M.) stereotypy scores 
during the 2 h following AMPH administration. Separate 
statistical analyses were conducted on the scores for the 
'sensitization' test sessions (injections 1-7), and the 
'challenge' session (tenth injection; see text). The symbols 
represent statistical differences between the indicated group 
and the other two groups: *P = 0.059, *P < 0.05 (see text for 
details). 
Fig. 1B). In contrast, there was no difference in 
either overall stereotypy or stereotyped snilTmg 
between female-l.78 and male animals following 
the 1st day of AMPH treatment (i.e. 1st test 
session; overall stereotypy: P = 0.18; repetitive 
sniffing: P > 0.5, based on the median test). 
Fig. 1A shows there was a progressive en- 
hancement in overall stereotypy scores with suc- 
cessive injections in both males and females 
(Friedman's analyses of variance conducted on 
the average scores for the 2-h test sessions were 
significant for all groups: males, X 2= 5.9, 
P = 0.05; female-1.78, X 2 = 14.2, P <  0.001; fe- 
male-2.6, X 2= 9.2, P---0.01). Analysis of the 
time course of behavior over each test session 
gave the same result. To determine if there were 
sex differences in the rate of sensitization the 
stereotypy ratings for male and female rats were 
compared using profile analyses. The prot'fle for 
male rats differed from the prot'de of both the 
female-l.78 and female-2.6 groups at the 
e = 0.059 level of significance (i.e. in Fig. 1A the 
curves are not parallel; F2.17 = 3.4, P = 0.059; 
F2.16 -- 3.4, P = 0.059, respectively). This inter- 
action was largely accounted for by the difference 
in scores between the first and second test 
sessions (i.e. injections 1-4), which was much 
greater for females than for males (Fig. 1A). A 
profde analysis comparing the curves of the two 
female groups resulted in a main effect of dose 
(F = 21.7, P < 0.001), but no interaction (i.e. the 
curves are parallel; F - -  2.4, P = 0.12). 
Fig. 1B illustrates the stereotyped snilTmg 
scores were also progressively enhanced in both 
male and female rats (Friedman's ANOVA's: 
males, Z 2 = 10.4, P =  0.005; female-l.78, 
Z2= 12.1, P = 0 . 0 0 2 ;  female-2.6, Z 2= 11.4, 
P = 0.003). Consistent with the differences in 
overall stereotyped behavior, there was a sex 
difference in the magnitude of the enhancement in 
stereotyped snilTmg over test sessions 1-7. The 
female-2.6 group showed a greater enhancement 
in stereotyped snift'mg than males (prot'de analysis 
interaction, F = 6.6, P = 0.008). Animals in the 
female-2.6 group also showed a greater rate of 
sensitization than those in the female-l.78 group 
(F = 5.6, P = 0.016). 
Challenge test. A further conservative test for 
sex differences in sensitization was conducted on 
the 10th injection day, when all female animals 
received a challenge with 1.78 mg/kg AMPH, and 
males again received 3.0 mg/kg. These doses did 
not distinguish the overall stereotypy ratings or 
repetitive snilTmg ratings of male and female rats 
following the first injection of AMPH (Fig. 1). 
After repeated AMPH treatment, however, a 
1.78 mg/kg challenge produced greater stereo- 
typed behavior in females than did a 3.0 mg/kg 
challenge in males (Fig. 1). Female-2.6 animals 
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given 1.78 mg/kg showed both greater overall 
stereotypy (P = 0.015, based on the median test) 
and stereotyped snilTmg behavior than did males 
given 3.0 mg/kg (U = 17, P = 0.024). The female- 
1.78 group showed greater overall stereotypy 
during the challenge test than did males 
(P = 0.025, based on the median test), but did not 
differ from males in stereotyped sniffing behavior 
(U = 43). 
It is interesting that the two female groups also 
differed from each other during the challenge test, 
even though both received the same dose of 
AMPH. Female-l.78 rats had significantly lower 
scores for repetitive sniffing (U = 11.5, 
P = 0.018), and also a non-significant trend for 
lower overall stereotypy scores (median test 
P -- 0.088)than female-2.6 animals. This suggests 
that pretreatment with the higher dose of AMPH- 
resulted in greater sensitization. 
Saline test. All animals received an injection of 
saline 3-4 days after the last AMPH treatment. 
The average ( + S.E.M.) overall stereotypy scores 
during the 1-h test session were 3.22 (+ 0.10) in 
the female- 1.78 group, 3.06 ( + 0.15) in the female- 
2.6 group, and 2.36 (+0.10) in males. These 
scores were significantly lower than the average 
1-h scores produced by the initial AMPH in- 
jection (4.11 + 0.16, 4.62 + 0.12, and 
3.98 + 0.14;P--  0.007, P = 0.01, a n d P  = 0.003; 
Wilcoxon signed-rank tests). The average scores 
for repetitive snilTmg behavior were also signifi- 
cantly lower during the saline test session than 
during the first AMPH test session (P's < 0.02). 
The two female groups did not differ in their re- 
sponse to an injection of saline (P's > 0.5). 
Changes in locomotor activity following repeated 
AMPH administration 
Habituation. In addition to rating stereotyped 
behavior, an automated method was used to con- 
tinuously record locomotor activity. Female-l.78 
and female-2.6 animals did not differ in the total 
distance traveled during habituation (data not 
shown), and therefore these data were pooled for 
statistically comparing males and females. Fe- 
males showed greater spontaneous locomotor ac- 
tivity during habituation than males (two-way 
ANOVA with repeated measures on one factor 
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influence of sex, F = 27.2, P < 0.001), but the dis- 
tance traveled during habituation did not change 
with repeated testing in either male or female rats 
(F's < 1.0). 
Amphetamine. Fig. 2 shows the effects of 
repeated A M P H  treatment on the time course of 
locomotor activity in each of the 3 groups. There 
was a significant change in the pattern of loco- 
motor activity in both female groups by the 4th 
injection of A M P H  (Figs. 2B and 3C; 
P 's  < 0.01), but the pattern of change was very 
different in the female-l.78 group than in the fe- 
male-2.6 group. During the first A M P H  test, fe- 
males in both groups showed enhanced loco- 
motion as the predominant response. During sub- 
sequent tests the female-l.78 group exhibited a 
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Fig. 2. The effects of repeated amphetamine (AMPH) treat- 
ment on the time course of locomotor activity (distance 
traveled) during 2-h test sessions, in the male and female rats 
described in Fig. 1. The mean number of inches traveled over 
each 10-rain interval following the 1st, 4th, 7th and 10th 
injections of AMPH are shown. The asterisks indicate test 
sessions that differ significantly from the first test session. 
Note that females were more sensitive to repeated AMPH 
treatment, showing significant changes in locomotion after 
only 4 injections, whereas males did not show significant 
changes until the 7th injection (see text for details). 
more rapid onset and longer duration of hyper- 
activity, but no change in the peak response 
(Fig. 2C). In contrast, female-2.6 animals showed 
an initial increase in locomotion, an intermediate 
phase of reduced locomotion (i.e. a 'stereotypy 
phase'), and finally, a late second period of in- 
creased locomotion (Fig. 2B). In male rats, 
significant alterations in the pattern of locomotion 
were not seen until the 7th A M P H  treatment 
(two-way ANOVA's with repeated measures on 
both factors: 1 st vs 4th: F = 1.64, P = 0.10; 1 st v s 
7th: F =  3.88, P <  0.001; 1st vs 10th: F =  3.85, 
P < 0.001; all interaction effects). These changes 
were confined largely to the first hour after 
A M P H  administration, and consisted of a brief 
initial period of enhanced locomotion followed by 
a more extended period of slightly decreased loco- 
motion, relative to that following the initial 
A M P H  treatment (Fig. 2). 
The changes in locomotor activity in male and 
female rats were consistent with the stereotypy 
ratings. In males and the female-l.78 group, the 
effect of repeated A M P H  treatment on the pattern 
of locomotion consisted largely of a more rapid 
onset of hyperactivity; and in the female-l.78 
group by an increase in the duration of the loco- 
motor response. Pretreatment with AMPH did 
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Fig. 3. The mean ( + S.E.M.) striatal DOPAC to DA ratios 
of AMPH-pretreated (A) and control (C) male and female 
rats (n's on Table I). Animals in the female-2.6 and female- 
1.78 groups were pooled (see text). The asterisk indicates 
that AMPH-pretreatment produced a significant increase in 
the DOPAC/DA ratio in female (P = 0.02), but not male 
rats. 
not result in the emergence of robust stereotyped 
behavior in these groups, as indicated by average 
stereotypy rating of 4-4.5 (normal alert to hyper- 
activity) and the absence of the multiphasic 
pattern of locomotion characteristic of the emer- 
gence of stereotypy 59. In contrast, following 
AMPH pretreatment the female-2.6 group had an 
average stereotypy rating near 6, which is consis- 
tent with the decrement in locomotor activity 
('stereotypy phase') seen during the peak drug 
effect 59. 
Neurochemical correlates of behavioral sensitization 
Table I shows the average concentrations of 
DA, DOPAC, 5-HT and 5-HIAA in the striatum 
and frontal cortex of AMPH-pretreated animals, 
and control animals that received no prior treat- 
ment. There were no differences in the concentra- 
tions of any of these neurochemicals between fe- 
male-l.78 and female-2.6 rats, or in metaboli- 
te/transmitter ratios, and therefore the data for 
these two groups were pooled for subsequent 
comparisons. Table I shows that AMPH-pre- 
treatment had no effect on DA or DOPAC con- 
centrations in either brain region, in male or fe- 
male rats. The concentrations of DOPAC and 
DA were also expressed as a ratio, because this 
ratio sometimes provides a sensitive index of DA 
metabolism 4"29'63. Fig. 3 illustrates that AMPH 
pretreatment produced a significant elevation in 
striatal DOPAC/DA ratios in female (t = 2.09, 
P = 0.046), but not male rats (t = 0.41). There 
was a non-significant tendency for higher 
DOPAC/DA ratios in AMPH pretreated fe- 
males, relative to AMPH-pretreated males 
(t = 1.84, P = 0.078). In addition, sensitized fe- 
males had higher DOPAC/DA ratios in the fron- 
tal cortex than control females (0.359 + 0.017 vs 
0.314 + 0.013; mean + S.E.M.), but this differ- 
ence was not statistically significant (t = 1.53, 
P = 0.14). 
There was an overall sex difference in the con- 
centration of 5-HT in the frontal cortex in control 
animals (males > females; t -- 2.35, P = 0.04; 
Table I). However, AMPH pretreatment had no 
effect on 5-HT, 5-HIAA or 5-HIAA/5-HT ratios 
in any group or structure, except for a small but 
statistically significant elevation in frontal cortex 
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5-HIAA concentrations in AMPH-pretreated fe- 
males (t = 2.01, P = 0.05; Table I). 
Sub-group analyses 
In response to a suggestion by R. Kuczenski 
(personal communication, December 198660 ) the 
male group was subdivided, post hoc, into two 
subgroups, based on their behavioral response to 
the tenth injection of AMPH. The animals were 
ranked according to the cumulative activity 
scores obtained over the first 60 min after AMPH 
administration, and then subdivided into those 
having relatively high activity scores (>6,250 
inches) and those having relatively low activity 
scores (<  6,250 inches). These groups will be re- 
ferred to as the HI and LO activity groups, re- 
spectively, and of course they differ significantly 
from one another because this division resulted in 
no overlap in their activity scores ( t--4.1,  
P = 0.003). It is suggested that the LO activity 
animals showed greater behavioral sensitization 
than HI activity animals for the following reasons. 
(1) The HI and LO subgroups did not differ in 
their behavioral response to the first injection of 
AMPH (t = 0.7), but came to differ only after 
repeated AMPH treatment. (2)The HI activity 
subgroup showed a small (19~o)but statistically 
significant elevation in activity between the first 
and tenth test sessions (6,337 + 612 vs 
7,567 + 580 inches; t = 3.6, P = 0.016, paired 
t-test), whereas the LO activity subgroup showed 
a 42 ~o decrease in activity between the first and 
tenth test sessions (7,047 + 850 vs 3,935 + 743 
inches; paired t =  3.1, P =  0.036). This latter 
pattern is characteristic of highly sensitized ani- 
mals, and indeed was the pattern of change seen 
in female-2.6 rats (illustrated in Fig. 2). In ad- 
dition, the reduced activity seen in LO activity 
males during the tenth test session was associated 
with vigorous stereotyped behavior (scores of 
6-8). Therefore, by dividing the group in this 
manner it is probable that the most sensitized 
animals were placed in one subgroup and the least 
sensitized in the other. Only after the subgroups 
were established by consideration of the be- 
havioral data were the neurochemical data 
reanalyzed. (It should be kept in mind that the 



































































































































































































































































































































































































































































































































































CTL HI LO 
Fig. 4. The mean ( + S.E.M.) striatal DOPAC/DA ratios in 
control (CTL) and AMPH-pretreated male (left) and female 
(right) rats. The AMPH pretreated groups were subdivided 
into high activity (HI) and low activity (LO) subgroups on the 
basis of their locomotor response to the last injection of 
AMPH, which was given over a week earlier (see text). The 
asterisk indicates that the AMPH-treated male animals fell 
into two neurochemically distinct subgroups (P = 0.027), but 
the females did not. (Group n's from left to right on the figure: 
6,6,5,6,8,9.) 
after the last injection of AMPH, and when the 
animals were in a non-drugged state.) 
Fig. 4 (left) shows the mean striatal DOPAC/ 
DA ratios for high (HI) and low activity (LO) 
males. LO males had significantly higher 
DOPAC/DA ratios than HI males (t = 2.21, 
P = 0.05). The HI activity males did not differ 
from control males, whereas there was a tendency 
for elevated striatal DOPAC/DA ratios in LO 
activity males, relative to controls (Fig. 4, left; 
t =  1.79, P =  0.053, 1-tail). There were no 
subgroup differences for any other neurochemical 
measure. The same analysis of females did not 
reveal any differences between HI versus LO ac- 
tivity animals for any neurochemical measure 
(e.g. Fig. 4, right). 
DISCUSSION 
The major question addressed here was 
whether there are sex differences in the sensiti- 
zation of stereotyped behavior or locomotion pro- 
duced by repeated AMPH treatment. The answer 
is yes. Repeated AMPH treatment produced a 
greater enhancement in overall stereotypy scores 
and ratings of repetitive sniffing in female than in 
male rats. Repeated AMPH treatment also pro- 
duced more robust changes in automated loco- 
motor activity counts in female than in male rats. 
63 
Sex differences in the sensitization produced by 
either AMPH or cocaine have now been reported 
in 6 different studies, using 5 different injection 
regimens 7"14'4°'44"5° (also, present study). Taken 
together, the available studies provide strong evi- 
dence for sex differences in the sensitization pro- 
duced by stimulant drugs, and establish that the 
effect is not peculiar to just one AMPH-induced 
behavior. 
It is important to consider whether sex differ- 
ences in behavioral sensitization are due to phar- 
macokinetic factors. Male rats metabolize 
AMPH more rapidly than females, primarily due 
to the influence of androgens on liver microsomal 
enzymes, and therefore, if males and females are 
given the same systemic dose of AMPH, brain 
levels are higher in females 3'1°'22'34. Of course, if 
male rats received a lower dose of AMPH than 
females, in terms of the amount of AMPH 
reaching the brain, this could account for the 
lower rate of sensitization in males. However, a 
sex difference in AMPH metabolism is probably 
not responsible for the sex difference in behavioral 
sensitization 6, for the following reasons. 
In all the studies showing a sex difference in 
sensitization to AMPH, male rats received a 
higher systemic dose of AMPH than females to 
compensate for the sex difference in AMPH 
metabolism 7'44'5° (also, present study). The sys- 
temic doses used to produce equivalent brain 
levels of AMPH in male and female rats were 
based on extensive experiments in which brain 
and striatal levels of AMPH were measured after 
systemic treatment with a wide range of doses 
(1-10 mg/kg), and in the same strain of rat as used 
in the behavioral experiments 3. Therefore, the sex 
difference in sensitization persists when males 
and females are treated with doses of AMPH 
known to produce comparable brain concentra- 
tions of the drug. In addition, female rats given a 
dose of AMPH that was estimated would pro- 
duce brain levels of AMPH 33 % lower than in 
males also showed more robust sensitization than 
males. The female-l.78 group showed a greater 
enhancement in overall stereotypy ratings than 
males (P = 0.059), and more robust changes in 
automated locomotor activity counts. Further- 
more, both female groups showed significant 
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changes in behavior by the fourth A M P H  test, but 
males did not show significant changes in be- 
havior until after the seventh test, suggesting that 
females sensitized more rapidly than males. 
Nevertheless, even after controlling for phar- 
macokinetic variables to insure that males and 
females receive equivalent brain levels of AMPH,  
females frequently show a greater acute be- 
havioral response to the drug than do males. This 
is clearly illustrated in Fig. 1 of Becker et al. 3, 
which shows striking sex differences and estrous 
cycle-related differences in AMPH-induced ro- 
tational behavior in the absence of differences in 
the brain levels of AMPH.  This sex difference 
often persists even if females are given a dose of 
A M P H  that produces lower brain levels of 
A M P H  than in a comparison group of males 
(present study and refs. 3,5,44,56). Therefore, 
controlling for the sex difference in A M P H  meta- 
bolism by titrating doses, as in the present study, 
does not 'control' for constitutional differences in 
the response of males and females to equivalent 
brain levels of AMPH.  But it is not meant to. In 
fact, it is probably impossible to completely com- 
pensate for the sex difference in the response to 
AMPH,  because this sex difference is not just due 
to sex differences in A M P H  metabolism, but to 
qualitative differences in the response of males 
and females to AMPH.  
That sex differences in the acute and chronic 
effects of A M P H  are not just due to pharmacody- 
namic factors is further supported by reports that 
females are more responsive than males to a wide 
range of activating stimuli 21"25"31"54, and that fe- 
males show more robust sensitization to repeated 
stress than do males. For example, females show 
a greater sensitization of the corticosterone re- 
sponse induced by repeated footshock stress than 
do males 17, and prior exposure to restraint stress 
results in a greater enhancement in AMPH-  
induced stereotyped behavior in females than in 
males 7. Obviously, sex differences in the sensiti- 
zation produced by stress cannot be due to phar- 
macodynamic factors. Therefore, to the extent 
that the sensitization produced by stimulants and 
stress represent a common phenomenon, as sug- 
gested by many reports 1"2'18'32'46'51, sex differ- 
ences in sensitization are not attributable to phar- 
macodynamic factors. 
This seemingly general sex difference in respon- 
sivity to activating stimuli, including AMPH, 
raises the question whether variation in the 
susceptibility to sensitization due to sex is due to 
sex differences in the propensity for change (sen- 
sitization), or whether it is a reflection of the re- 
sponsiveness to an acute injection of AMPH.  
Stated another way, are the constitutional differ- 
ences responsible for individual variation in the 
acute response to A M P H  also responsible for 
individual variation in the susceptibility to sensiti- 
zation? If so, the response to the first injection of 
AMPH should predict the susceptibility to sensi- 
tization. This was not the case in the present 
study, because highly sensitized animals did not 
differ from less sensitized animals following the 
first injection of AMPH.  Robinson 4a reached a 
similar conclusion in a study on the sensitization 
of AMPH-induced rotational behavior. Perhaps 
most convincing are studies by Shuster et al.58 on 
the sensitization produced by repeated cocaine 
treatment in inbred strains of mice. These resear- 
chers dissociated the acute response to cocaine 
and the susceptibility to sensitization, concluding 
that, "the initial response to cocaine and the de- 
velopment of sensitization are controlled by 
different genetic determinants" (p. 185). There- 
fore, the sex difference in sensitization is probably 
not simply an extension of a sex difference in the 
initial responsiveness to A M P H  (see ref. 45 for a 
more complete discussion of this point). 
Most of the behaviors sensitized by AMPH 
are largely due to AMPH-stimulated DA re- 
lease ~ 1,19, and it has been suggested that sensiti- 
zation is due to enduring changes in mesotelence- 
phalic DA systems (ref. 48 for review). In the 
present study A M P H  pretreatment had no effect 
on 'resting' DA or DOPAC concentrations in the 
striatum or frontal cortex, but AMPH-pretreated 
female rats did have significantly higher DOPAC/  
DA ratios than non-treated control animals. In 
some experimental situations an increase in meta- 
bolite/transmitter ratios reflects enhanced 
neurotransmitter utilization 4'29"63, but unfor- 
tunately, changes in metabolism are not always a 
reliable indicator of utilization 9'67. The change in 
DOPAC/DA ratios found here is particularly 
difficult to interpret because it was not ac- 
companied by a significant change in metabolite 
concentrations, as is usually the case if utilization 
is enhanced 27'53. Nevertheless, the elevation in 
DOPAC/DA ratios seen in AMPH-pretreated fe- 
male rats may reflect a sensitization-related en- 
hancement in striatal DA metabolism, for the 
following reasons. 
First, the results were replicated in an indepen- 
dent experiment using a similar injection regimen, 
and most importantly, the elevation in meta- 
bolite/transmitter ratios was accompanied by a 
significant elevation in striatal homovanillic acid 
concentrations in this experiment 7. Similarly, 
Robinson and Camp 82 found that DOPAC/DA 
ratios and DOPAC concentrations were elevated 
in the striatum and nucleus accumbens of female 
rats given a regimen of escalating doses of 
AMPH, and Watanabe 66 reported a similar ob- 
servation in male rats. In a related experiment, 
Schuster et al. 57 found that methylphenidate pre- 
treatment in mice enhanced striatal DA turnover, 
as indicated by the rate of decline in DA after 
tyrosine hydroxylase inhibition, and this was 
accompanied by increased DOPAC/DA ratios 
but no change in DA or DOPAC concentrations. 
In summary, sensitization-related increases in 
striatal DOPAC/DA ratios are typically asso- 
ciated with an increase in striatal DA metabolism, 
supporting the argument that the elevated 
DOPAC/DA ratios reported here do reflect a 
change in striatal DA metabolism. Metabo- 
lite/transmitter ratios are probably more sensitive 
indicators of changes in metabolism than metabo- 
lite concentrations alone, and this is why just the 
ratio was elevated in this particular study. To the 
extent that an increase in striatal DA metabolism 
is indicative of increased DA utilization, the 
present results are consistent with the idea that 
AMPH pretreatment enhances striatal DA utili- 
zation in female animals. This idea is further sup- 
ported by reports that in female rats, prior expo- 
sure to AMPH enhances AMPH-, potassium- 
and electrical stimulation-induced striatal DA re- 
lease measured in vitro 8,47,68. 
In female rats sensitization to AMPH is consis- 
tently accompanied by both an increase in striatal 
DA metabolism (present study and refs. 7,52), 
and in striatal DA release in vitro 8,5°,68. In male 
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rats, however, the picture is not as clear. AMPH- 
pretreated male rats frequently do not show en- 
during changes in basal striatal DA metabolism 
or util ization 7'28'36'38 (cf. ref. 66). If changes in 
striatal metabolism are related to the development 
of behavioral sensitization, why do both males 
and females show behavioral sensitization but 
only females show increases in striatal DA meta- 
bolism? There are a number of possible answers 
to this question. One is that changes in striatal 
DA activity are not causally related to behavioral 
sensitization. But like females, male rats do show 
a sensitization-related increase in striatal DA 
utilization/release when measures are made 
following an additional AMPH 'challenge '26, 
28,38,47. Perhaps measures of basal DA activity do 
not provide a sensitive index of the neural changes 
produced by repeated AMPH treatment, and the 
change is primarily characterized by an enhanced 
response to a subsequent challenge 48. Changes in 
basal striatal DA activity may be more apparent 
in females because the sex difference in behavioral 
sensitization is accompanied by a sex difference 
in the magnitude of the neurochemical conse- 
quences of AMPH treatment. It is also possible 
that the kinds of neurochemical measures re- 
ported here do not provide a true reflection of 
basal conditions, but a rapid and exaggerated re- 
sponse to stress 1. This would be expected to be 
more pronounced in females  21,25'45. The idea that 
changes in striatal DA metabolism are related to 
the development of behavioral sensitization is 
further supported by analysis of the high and low 
activity subgroups. The presumably more highly 
sensitized males (LO activity) had significantly 
greater DOPAC/DA ratios than HI activity 
males. The difference between the two subgroups 
was only marginally significant, but is reliable, 
because the effect has been replicated 7. 
It is particularly interesting that the male group 
was divisible into two neurochemically dis- 
tinguishable subgroups and the female group was 
not. This finding has also been replicated 7, and it 
suggests that male populations may be more 
heterogeneous in their response to repeated 
AMPH treatment than female populations. This 
greater heterogeneity could make it relatively diffi- 
cult to identify neurochemical correlates of sensi- 
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tization in male rats 48. Many factors may contri- 
bute to heterogeneity in male populations. For 
example, it was previously suggested that a testi- 
cular hormone attenuates the development of sen- 
sitization 44'5°, and therefore it is possible that HI 
activity males have higher levels of circulating 
androgens than LO activity males. Evidence to 
support the idea that males constitute a more 
variable or heterogeneous population than fe- 
males for many biological traits was recently 
reviewed by Juraska 2°. 
In summary, the results reported here, in com- 
bination with other studies, suggest that: (1)the 
repeated administration of psychomotor stimu- 
lant drugs produces greater behavioral sensiti- 
zation in female than in male ratsT"14"44'5°; 
(2) neural correlates of sensitization may be more 
readily identifiable in female than in male rats; 
and (3) as a group, males may be more hetero- 
geneous than females in their susceptibility to 
sensitization. It is interesting that there are similar 
sex differences in the sensitization produced by 
repeated intermittent stress TM 7. The available evi- 
dence suggests there is a general sex difference in 
the responsiveness of brain DA systems to repeti- 
tive activation, and that females are more suscep- 
tible to the sensitization produced by repeated 
exposure to activating stimuli than males. The 
neurobiological basis and adaptive significance of 
such a sex difference is unknown. 
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